An HNF1α truncation associated with maturity-onset diabetes of the young impairs pancreatic progenitor differentiation by antagonizing HNF1β function

Graphical abstract

Highlights

- MODY3 patient and CRISPR/Cas9 HNF1α p291fsinsC mutated iPSC lines are generated
- Mutant iPSCs show deficient pancreatic progenitor and β cell differentiation
- Mutant truncated HNF1α protein binds wild-type HNF1β protein to hinder its function
- HNF1β overexpression in MODY3 iPSC line partially rescues β cell differentiation

Authors

Ana-Maria Cujba, Mario E. Alvarez-Fallas, Sergio Pedraza-Arevalo, ..., Andrew T. Hattersley, Fiona M. Watt, Rocio Sancho

Correspondence

rocio.sancho@kcl.ac.uk

In brief

Cujba et al. use human MODY3 patient and CRISPR/Cas9 edited iPSC lines to show that the HNF1α p291fsinsC mutation results in the expression of a mutant truncated HNF1α protein that interacts with wild-type HNF1β protein and inhibits its function, impairing pancreatic progenitor and β cell differentiation.
An HNF1α truncation associated with maturity-onset diabetes of the young impairs pancreatic progenitor differentiation by antagonizing HNF1β function

Ana-Maria Cujba,1,5 Mario E. Alvarez-Fallas,1,5 Sergio Pedraza-Arevalo,1 Anna Laddach,2 Maggie H. Shepherd,3 Andrew T. Hattersley,3 Fiona M. Watt,1 and Rocio Sancho1,4,6,*

1Centre for Stem Cells and Regenerative Medicine, King’s College London, London, UK
2Francis Crick Institute, London, UK
3University of Exeter Medical School, Exeter, UK
4Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany
5These authors contributed equally
6Lead contact
*Correspondence: rocio.sancho@kcl.ac.uk
https://doi.org/10.1016/j.celrep.2022.110425

SUMMARY

The HNF1αp291fsinsC truncation is the most common mutation associated with maturity-onset diabetes of the young 3 (MODY3). Although shown to impair HNF1α signaling, the mechanism by which HNF1αp291fsinsC causes MODY3 is not fully understood. Here we use MODY3 patient and CRISPR/Cas9-engineered human induced pluripotent stem cells (hiPSCs) grown as 3D organoids to investigate how HNF1αp291fsinsC affects hiPSC differentiation during pancreatic development. HNF1αp291fsinsC hiPSCs shows reduced pancreatic progenitor and β cell differentiation. Mechanistically, HNF1αp291fsinsC interacts with HNF1β and inhibits its function, and disrupting this interaction partially rescues HNF1β-dependent transcription. HNF1β overexpression in the HNF1αp291fsinsC patient organoid line increases PDX1+ progenitors, while HNF1β overexpression in the HNF1αp291fsinsC patient iPSC line partially rescues β cell differentiation. Our study highlights the capability of pancreas progenitor-derived organoids to model disease in vitro. Additionally, it uncovers an HNF1β-mediated mechanism linked to HNF1α truncation that affects progenitor differentiation and could explain the clinical heterogeneity observed in MODY3 patients.

INTRODUCTION

Maturity-onset diabetes of the young 3 (MODY3) accounts for 30%–70% of all MODY cases. Though classified under the same subtype, more than 200 different heterozygous mutations in the hepatocyte nuclear factor 1α (HNF1α) gene have been associated with MODY3 (Bellanne-Chantelot et al., 2008; Ellard and Colclough, 2006; Frayling et al., 1997; Yamagata et al., 1996). Not surprisingly, patients with MODY3 show a highly heterogeneous clinical phenotype influenced by type and position of HNF1α mutation (Bellanne-Chantelot et al., 2008), patient genetic background (Lango Allen et al., 2010), and environmental effects both before and after birth (Hattersley, 1998; Stride et al., 2002). This heterogeneity is reflected in the treatment required by patients to control diabetes. Patients are initially controlled with diet and sulfonylureas but at variable ages require additional therapy such as insulin (Hattersley, 1998; Lehto et al., 1997; Pearson et al., 2000). However, the molecular mechanism linking specific HNF1α mutations to β cell development remains elusive.

Mutations in the dimerization domain may exhibit different impacts in HNF1α function, related to the impaired binding to co-factors and DNA targets. Mutations in the DNA-binding homeodomain are related to several diseases besides MODY3 (Valkovicova et al., 2019). However, there is not a clear link between reduced DNA binding and reduced transactivation activity, so the impact of these mutations is still uncertain. Mutations in the HNF1α promoter may alter its transcriptional activation, leading to crucial consequences, which are probably the reason for the low rate observed for these mutations. Other mutations that alter the cellular localization of HNF1α and its interaction with other factors and DNA have been found at the transactivation domain (Cubuk and Yalcin Capan, 2021; Valkovicova et al., 2019). Thus, the location of the HNF1α-specific mutation is crucial for the mechanism and exhibited effects.

One of the transactivation domain mutations is HNF1αp291fsinsC. This mutation is the most frequent in MODY3 patients and is found in 20%–50% of cases (Frayling et al., 1997; Kaisaki et al., 1997; Yamagata et al., 1996). Insertion of a cytosine (C) in the polycytidine tract of codon 291 (p291fsinsC) of HNF1α results in a frameshift mutation and premature stop codon (Kaisaki et al., 1997). Patients with this mutation exhibit more severe clinical phenotypes than other HNF1α truncated patients, often showing symptoms similar to those of type 1 diabetes (Lebenthal et al., 1997).
Figure 1. MODY3-derived iPSCs show impaired differentiation to pancreas progenitors
(A) Schematic representation of the HNF1α p291fsinsC mutation.
(B) Schematic depicting the 14-day differentiation protocol of HNF1α WT/MODY3 iPSCs into PPs. Markers used at each stage are indicated.
(C) qRT-PCR analysis of key iPSC, DE, PGT, and PF markers in HNF1α WT/HNF1α MODY3 lines during differentiation.
(D) Representative IF staining for OCT4 and SOX17 (DE stage) and HNF1β (PF stage) in HNF1α WT/HNF1α MODY3 lines.
(E) Quantification of OCT4+, SOX17+, and HNF1β+ cells detected by IF.
(F) qRT-PCR analysis of PP markers in HNF1α WT/HNF1α MODY3 lines.
(G) Representative IF staining for PDX1, NKX6.1, and SOX9 at the PP stage in HNF1α WT/HNF1α MODY3 lines.

(legend continued on next page)
2018), and in some cases can develop hepatocellular adenoma (Reznik et al., 2004). Therefore, this mutation does not recapitulate other transactivation domain MODY3 mutants. Interestingly, HNF1α<sup>p291fsinsC</sup> phenotypes in MODY3 have been attributed to a dominant negative effect due to the formation of a truncated HNF1α protein (Okita et al., 1999; Vaxillaire et al., 1999; Yamagata et al., 1998) or haploinsufficiency mediated through nonsense-mediated decay (Harries et al., 2004). However, HNF1α<sup>p291fsinsC</sup> mice do not develop diabetes (Pontoglio et al., 1998) and HNF1α<sup>p291fsinsC</sup> mice show growth retardation, impaired insulin release, and aerobic glucose metabolism, but unlike MODY3 patients suffer from other renal and kidney complications due to the pleiotropic effect of complete loss of HNF1α (Lee et al., 1998; Pontoglio et al., 1996, 1998; Servitja et al., 2009). This shows that mice do not fully recapitulate MODY3 pathogenesis triggered by nonsense and missense mutations. Genetically engineered human embryonic stem cells (hESCs) lacking one or both HNF1α alleles show decreased insulin secretion, glycolysis, mitochondrial function, and developmental bias toward α cells upon differentiation (Cardenas-Diaz et al., 2019). Human induced pluripotent stem cell (iPSC) lines derived from patients with HNF1α mutations have been generated, but their ability to differentiate into β cells has not been thoroughly addressed (Stepniewski et al., 2015; Yabe et al., 2015, 2019). Interestingly, overexpression of truncated forms of HNF1α in mice results in more severe phenotypes of reduced β cell growth and insulin secretion (Hagenfeldt-Johansson et al., 2001; Yamagata et al., 2002), suggesting that potential truncated forms of HNF1α caused by the p291fsinsC mutation might have additional HNF1α-independent functions, possibly via its interaction with other HNF members. Even though HNF1α homologous protein HNF1β has a broader tissue expression (Cereghini et al., 1992), the ventral endoderm is the main area affected by homozygous deletion of this protein (Lokmane et al., 2008). Expression of HNF1β appears as early as the primitive gut tube stage of differentiation, and it was demonstrated to be fundamental for the determination of multipotent progenitor cells (De Vas et al., 2015; El-Khairi and Vallier, 2016). Indeed, full deletion of HNF1β expression in mice results in pancreas agenesis, while heterozygous expressing mice have pancreatic hypoplasia and kidney-related phenotypes (De Vas et al., 2015). Similarly, mutations affecting HNF1β in humans cause phenotypes mainly associated with kidney disorders, diabetes mellitus, and MODY (Bockenhauer and Jauregui-Beir, 2016).

Although the dimerization between the two homologous proteins has been since long described (Mendel et al., 1991; Rey-Campos et al., 1991) and tissues co-expressing HNF1α and HNF1β display comparable abundance of transcripts (Mendel et al., 1991), implications of an altered interplay between these two proteins are poorly studied (Balamurugan et al., 2016; Kitanaka et al., 2007). Studies on knockout models of either one or the other transcription factor (De Vas et al., 2015; Servitja et al., 2009) alongside general description of affected targets (Verhave et al., 2016) highlighted a set of genes which appear to be regulated by either one or the other, as well as genes potentially regulated by both, therefore hinting at a possible heterodimeric dynamic that could affect MODY3 development.

Here, we use an hiPSC-derived progenitor organoid system to understand the mechanism of the p291fsinsC mutation in MODY3. We uncovered a severe developmental defect at the pancreatic progenitor stage in differentiating patient-derived and CRISPR/Cas9-engineered HNF1α<sup>p291fsinsC</sup> heterozygous hiPSCs, which can be explained by the antagonizing effect of HNF1α<sup>p291fsinsC</sup> on HNF1β function.

**RESULTS**

**MODY3-derived iPSCs show impaired differentiation to pancreas progenitors**

To investigate whether the HNF1α<sup>p291fsinsC</sup> mutation in MODY3 patients has any developmental effect on pancreatic progenitor (PP) differentiation, we used five MODY3 patient-derived hiPSC lines (hereafter, HNF1α<sup>MODY3</sup>) alongside five healthy donor hiPSC lines (hereafter, HNF1α<sup>WT</sup>) from the Human Induced Pluripotent Stem Cell Initiative (HiPSci) bank (Streeter et al., 2017), confirmed to have no gross chromosomal abnormalities, high pluripotency score, and low novelty score (Figures S1A and S1B). Both sequencing and exome sequencing analysis confirmed that all five studied MODY3 hiPSC lines have the HNF1α<sup>p291fsinsC</sup> mutation in exon 4 (Figures S1C and S1D). Clinical data confirmed heterogeneous disease phenotypes among the MODY3 patients (Figure S2A). Both HNF1α<sup>WT</sup> and HNF1α<sup>MODY3</sup> iPSC lines were differentiated to PP, showing distinctive cell morphologies at the end of the differentiation (Figure S2B). Upon differentiation toward the pancreatic lineage in vitro, both HNF1α<sup>WT</sup> and HNF1α<sup>MODY3</sup> lines efficiently reached the definitive endoderm (DE) stage, marked by SOX17 and decreased OCT4 expression (Figures 1A–1C). Although residual OCT4 expression was observed in HNF1α<sup>MODY3</sup> during DE and primitive gut tube (PGT) stages due to patient-to-patient heterogeneity (Figures 1C–1E and S2C), none was found at later stages of differentiation (Figure 1C). HNF1α expression was first detected at the PGT stage and increased throughout posterior foregut (PF) and PP stages in HNF1α<sup>WT</sup> lines. HNF1α expression was slightly, but not significantly, reduced in the HNF1α<sup>MODY3</sup> lines during PGT and PP, possibly due to nonsense-mediated mRNA decay, as reported previously (Figure 1C) (Harries et al., 2004; Yabe et al., 2019), but recovered at the PP stage to levels comparable with those in the HNF1α<sup>WT</sup> lines. Despite the slight differences in expression dynamics, both HNF1α<sup>WT</sup> and HNF1α<sup>MODY3</sup> lines reached PF stage at comparable levels, as revealed by the similar
A HNF1α WT
CRISPR-CAS9
p291finsC
mutation
IPSCs

B HNF1α WT/CRISPR
Definitive endoderm
Primitive gut tube
Posterior foregut
Pancreatic progenitor
IPSCs
DE
PGT
PF
PP

C gRNA
GACAGTGACGCGGCCCCCCCCAGGGCC
ssDNA template
GACATTATTACGGCCTCCCTCCAGGGCC
p291finsC
mutation (MODY3)

D OCT4
SOX17
HNF1β
PDX1
NKKX6.1
SOX9

E HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT

F HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT

G OCT4 (DE)
SOX17 (DE)
HNF1β (PF)

H PDX1
NKKX6.1

I HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT

J PDX1
NKKX6.1

K HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT
HNF1α WT

(legend on next page)
percentage of HNF1β+ cells and HNF1β mRNA expression at the PGT and PF stage (Figures 1C–1E and S2D).

While HNF1xWT lines efficiently expressed the PP markers PDX1, NKX6.1, SOX9, and CK19 upon further differentiation to PP stage, HNF1xMODY3 lines showed a sharp decrease in PDX1, NKX6.1, and SOX9 expression (Figure 1F), confirmed by immunofluorescence and flow cytometry analysis of protein levels (Figures 1G–1J and S2E–S2G). Concomitantly, the PDX1/NKX6.1 double-positive progenitor population, crucial for subsequent β cell development (McGaugh and Nostro, 2017; Russ et al., 2015), was reduced 4-fold in HNF1xMODY3 lines when compared with HNF1xWT lines (Figures 1J and S2G).

Since some of the HNF1xMODY3 lines contained residual OCT4 expression at the DE stage upon differentiation (Figure S2C), we performed enrichment of DE cells for the HNF1xMODY3 line that had residual OCT4+ cells in the DE stage alongside an HNF1xWT line prior to PP differentiation (Figure S3). At the DE stage, both the HNF1xMODY3 and HNF1xWT lines contained a comparable amount of the DE marker CXCR4+ cells as detected by immunofluorescence (IF) (Figure S3A). We detached the DE cells and performed magnetic sorting to purify the CXCR4+ and CXCR4− fractions (Figures S3B and S3C). We confirmed the enrichment of CXCR4 by qPCR analysis and observed that the HNF1xMODY3 line seemed to have higher expression levels of CXCR4 in all the tested fractions when compared with the HNF1xWT line (Figure S3C). We then replated the purified fractions to continue their differentiation to PP. The sorting process clearly affected the ability of both CXCR4+ and CXCR4− fractions to reattach. However, while the HNF1xWT line recovered and formed a monolayer after 5 days toward PP differentiation conditions (Figure S3D), the HNF1xMODY3 sorted CXCR4+ and CXCR4− DE cells failed to reattach and eventually died within 5 days (Figure S3D). Therefore, their potential to differentiate to PP could not be evaluated. However, the levels of OCT4 in the DE stage do not correlate with PP phenotype severity (measured as percentage of PDX1+/NKX6.1+ cells) observed in the MODY3 lines (Figure S3E).

Altogether, these data suggest that the heterozygous p291fsinsC mutation in HNF1xMODY3 lines impairs PP differentiation, and this is not dependent on the residual OCT4 expression at DE stage in some of the HNF1xMODY3 lines.

Genetically engineered HNF1x_p291fsinsC mutant iPSCs recapitulate the PP differentiation defect observed in MODY3 iPSCs

To confirm whether the phenotype observed in the patient HNF1xMODY3 lines was solely due to the frameshift mutation in HNF1x and to address the heterogeneity that arises from genetic backgrounds of patient lines, we used CRISPR/Cas9 to engineer the p291fsinsC mutation in an HNF1xWT iPSC line (Figures 2A–2C) and tested its ability to differentiate toward PPs (Figure 2B). Successful genome editing of the HNF1xWT iPSC line was confirmed by sequencing and restriction digest with the newly integrated BsaRI restriction site (Figures 2D, S4A, and S4C) in three CRISPR clones harboring the HNF1x_p291fsinsC mutation in heterozygosity (HNF1xCRISPR). We analyzed the pluripotency of the HNF1xCRISPR lines and their karyotype (Figures S4D and S4E). The three HNF1xCRISPR lines showed OCT4, NANOG, and SOX17 expression, reflecting their pluripotency (Figure S4D). As previously reported for expansion and CRISPR/Cas9 editing of iPSCs in vitro, we observed one or two commonly found chromosomal abnormalities (Assou et al., 2020; Rebuzzini et al., 2015) after low-pass sequencing analysis (Figure S4E). However, no abnormalities were detected in chromosome 12, where CRISPR/Cas9 editing of HNF1x locus was performed successfully (Figure S4F). During differentiation into PPs, isogenic HNF1xWT and mutant HNF1xCRISPR lines clones efficiently reached DE and PF stages as marked by an increase in SOX17 and HNF1β expression and downregulation of OCT4 (Figures 2E–2G). However, similarly to HNF1xMODY3 lines, a significant downregulation of PDX1 and NKX6.1 was observed at the PP stage in all three HNF1xCRISPR clones compared with HNF1xWT, with no significant downregulation of HNF1α and HNF1β observed at this stage (Figure 2H). Furthermore, the percentage of PDX1− and NKX6.1-positive cells in the HNF1xCRISPR clones was reduced by ~3-fold and ~10-fold, respectively (Figures 2I and 2J). Accordingly, the percentage of PDX1/NKX6.1 double-positive cells was drastically reduced in all HNF1xCRISPR lines compared with isogenic HNF1xWT lines as detected by flow cytometry (Figure 2K). These data demonstrate that the CRISPR/Cas9-engineered iPSCs fully recapitulate the PP differentiation defect observed in HNF1xMODY3 patient iPSC lines.

Figure 2. Genetically engineered HNF1x_p291fsinsC mutant iPSCs recapitulate the pancreas progenitor differentiation defect observed in MODY3 iPSCs

(A) Schematic depicting the strategy to generate HNF1xCRISPR iPSC lines.

(B) Schematic depicting the 14-day differentiation protocol of HNF1xWT/HNF1xCRISPR iPSCs into PPs. Markers used at each stage are indicated.

(C) Guide RNA sequence (green) with protospacer adjacent motif sequence (red) and single-stranded DNA template used to engineer the p291fsinsC mutation in HNF1xWT line.

(D) DNA chromatograms of the HNF1xWT iPSC line and the three engineered heterozygous p291fsinsC mutant HNF1xCRISPR iPSC lines. Arrows indicate heterozygosity.

(E) Representative IF staining for OCT4 and SOX17 (DE stage) in HNF1xWT/HNF1xMODY3 lines.

(F) Representative IF staining for HNF1β (PF stage) in HNF1xWT/HNF1xCRISPR lines.

(G) Quantification of OCT4*, SOX17*, and HNF1β* cells detected by IF.

(H) qRT-PCR analysis of PDX1, NKX6.1, HNF1α, and HNF1β at the PP stage.

(I) Representative IF staining for PDX1 and NKX6.1 (PF stage) in HNF1xWT/HNF1xCRISPR lines.

(J) Quantification of the percentage of PDX1* and NKX6.1* PPs cells detected by IF.

(K) Representative flow cytometry dot plot for PDX1 and NKX6.1 co-staining in HNF1xWT/HNF1xCRISPR PPs.

n = 3 individual differentiations (G, H, and J). Error bars are SEM. p values shown on graphs only for significant differences determined by multiple t tests (G, H, and J). ns, non-significant. Scale bars, 50 μm (E, F, and I). See also Figure S4.
Figure 3. Derivation of pancreas progenitor organoids to study p291fsinsC mutation
(A) Schematic depicting the strategy to expand progenitor organoids from HNF1αWT/HNF1αMODY3/HNF1αCRISPR lines.
(B) Representative bright-field images of PP organoids from HNF1αWT/HNF1αMODY3/HNF1αCRISPR lines.
(C) Representative IF staining for PDX1 and KI67 in HNF1αWT/HNF1αMODY3/HNF1αCRISPR progenitor organoids.
(D) Representative flow cytometry staining for PDX1 and KI67 in HNF1αWT/HNF1αMODY3/HNF1αCRISPR progenitor organoids.
(E) Quantification of PDX1+, KI67+, and PDX1+KI67+ cells detected by flow cytometry. n = 4–5 independent experiments.

(legend continued on next page)
Additionally, we addressed whether correcting the HNF1αp291fsinsC mutation in the HNF1αMODY3 iPSC lines was sufficient to rescue the PP-impaired progenitor phenotype observed. To this end, we performed CRISPR/Cas9 editing in one of the HNF1αMODY3 iPSC lines that showed residual OCT4 expression at the DE stage (Figure S4F). We confirmed successful correction of the mutation by sequencing (Figures S4G and S4H). Similar to the CRISPR/Cas9-edited HNF1αCRISPR lines, the HNF1αCRISPR-CORRECTED line showed expression of pluripotency markers NANOG, OCT4, and SOX17 and presented one chromosomal aberration (Figures S4D and S4E). Differentiation of HNF1αCRISPR-CORRECTED line to DE resulted in similar percentage of OCT4+ cells when compared with its parental HNF1αMODY3 iPSC line (Figures S4I and S4J). However, while the parental HNF1αMODY3 line showed a clear impairment in PDX1+/NKX6.1+ cell differentiation at the PP stage, the HNF1αCRISPR-CORRECTED line showed PDX1+/NKX6.1+ percentages similar to the HNF1αWT line (Figures S4L and S2G). While correcting the p291fsinsC mutation in the HNF1αMODY3 line efficiently reverted the PP defect observed in HNF1αMODY3 lines (Figures S4K and S4L), it did not rescue the residual OCT4 levels after differentiation to the DE stage (Figures S4I and S4J). Collectively, our data suggest that the p291fsinsC mutation in HNF1αMODY3 induces the PP differentiation defect and that the heterogeneity in DE differentiation among MODY3 lines is patient specific and independent of residual OCT4+ cells in DE (Figures 2C–2E and S4I).

**Differentiation of PP-derived organoids to β-like cells is drastically reduced in HNF1αMODY3 and HNF1αCRISPR lines**

One of the key limitations of two-dimensional (2D) models of pancreatic differentiation is the inability to recapitulate the proliferative environment and cell-cell interactions crucial for morphogenesis during pancreas development. We developed a three-dimensional (3D) organoid model system to expand PPs and further characterize the HNF1αMODY3 lines. We firstly established HNF1αWT expandable progenitor organoids by adapting published protocols (Boj et al., 2015; Huch et al., 2013). Our method allowed the expansion of PP for at least 15 population doublings (Figures S5A and S5B). Single PP cells formed spheroid organoids with a lumen within 7 days in Matrigel (Figure S5C). During the expansion phase, 72.9% of the organoid cells were PDX1+ and 8.35% were NKX6.1+ (Figure S5D). HNF1αWT organoids retained progenitor marker expression up to passage 15 (Figures S5E and S5F) and efficiently differentiated toward β-like cells in suspension (Figures S5G and S5H). We then established organoid lines from HNF1αWT, HNF1αMODY3, and HNF1αCRISPR PPs obtained in 2D and analyzed their morphology, marker expression, and proliferative capacity in basal conditions (Figures 3A and 3B). Consistent with results from the PP stage, PDX1+ cells were significantly decreased, while levels of proliferation marked by Ki67 were maintained at comparable levels. PDX1+Ki67+ cells were significantly decreased in both HNF1αMODY3 and HNF1αCRISPR organoids in comparison with HNF1αWT organoids (Figures 3C–3E). Despite comparable gross morphology in all three organoid lines (Figure 3B), HNF1αMODY3 organoids showed regions marked by a slight decrease in E-CADHERIN HNF1α+ cells when compared with HNF1αWT organoids (Figure 3F). However, no significant differences in HNF1α mRNA levels were observed in HNF1αMODY3 or HNF1αCRISPR organoids compared with HNF1αWT organoids (Figure 3G). Besides E-cadherin expression, which is known to maintain islet structure and function (Rogers et al., 2007), we also investigated the effect of the p291fsinsC mutation on the tight junction protein Zona occludens-1 (ZO1) expression (Figures 3H and 3I). Interestingly, ZO1 expression had a more homogeneous and higher expression across the HNF1αMODY3 and HNF1αCRISPR organoids compared with the apical distribution in the HNF1αWT organoids (Figures 3H and 3I), indicating a potential disorganization of cell polarity in the HNF1αMODY3 and HNF1αCRISPR organoids, as has been reported in islets from HN1αp291fsins291C transgenic mice (Yamagata et al., 2002).

After differentiation to β-like cells (Figure 4A), HNF1αMODY3 and HNF1αCRISPR organoids displayed irregular morphologies with budding cell clusters contrasting the well-defined boundaries observed in HNF1αWT organoids (Figure 4B). In agreement with the reduction of PP markers in HNF1αMODY3 and HNF1αCRISPR lines (Figures 1 and 2), a significant decrease in INS, SST, and GCG expression and in the percentage of INS+ cells were observed at the endpoint of differentiation of HNF1αMODY3 and HNF1αCRISPR organoids to β-like cells when compared with HNF1αWT organoids (Figures 4C–4E). However, no significant differences in HNF1α, HNF1β, or E-cadherin were observed at the mRNA or protein levels between HNF1αWT and HNF1αMODY3 lines at the final stage of differentiation (Figures 4C and S5I). Though not absent, INS+ cells were reduced from the 30% INS+ cells in the WT organoids (Figures 4C–4E). Consistent with the reduction in the percentage of INS+ cells in the HNF1αMODY3 and HNF1αCRISPR organoids, we observed a severe decrease in insulin secretion upon glucose stimulation (Figure 4F), indicating that the resulting INS+ cells in the HNF1αMODY3 and HNF1αCRISPR organoids are non-functional. Despite of one of the replicates in the HNF1αCRISPR lines showing basal glucose-independent secretion, the secreted insulin levels did not further increase upon high glucose stimulation (Figure 4F).
Figure 4. Differentiation of pancreas progenitor-derived organoids to functional β-like cells is reduced in HNF1αMODY3 and HNF1αCRISPR lines

(A) Schematic depicting the strategy to differentiate PP organoids to β-like cells.
(B) Representative bright-field images of HNF1αWT/HNF1αMODY3/HNF1αCRISPR PP organoids after differentiation.
(C) qRT-PCR analysis of HNF1α, HNF1β, E-CADHERIN, insulin (INS), glucagon (GCG), and somatostatin (SST) in differentiated HNF1αWT/HNF1αMODY3/HNF1αCRISPR PP organoids. n = 5 individual differentiations.
(D) Representative IF staining for INS, SST, and GCG in HNF1αWT/HNF1αMODY3/HNF1αCRISPR organoids.
(E) Quantification of INS⁺, SST⁺, and GCG⁺ cells detected by IF. n = 9 organoids from three individual differentiations.
(F) Glucose-stimulated insulin secretion (GSIS) comparing HNF1αWT organoid lines versus HNF1αMODY3 and HNF1αCRISPR organoid lines, respectively. n = 3 independent differentiations.

Error bars are SEM. p values shown only for significant differences determined by multiple t tests (E), one-way ANOVA followed by Tukey's multiple comparison test (C), or two-way ANOVA followed by Sidak's multiple comparison test (F). ns, non-significant. Scale bars, 100 μm (B) and 50 μm (D).
This is consistent with them being non-functional residual β cells. Collectively, these data suggest that the inhibitory effect of the HNF1αp291fsinsC mutation on PP differentiation results in an overall reduction of β-like cell differentiation and function.

**HNF1αp291fsinsC interacts with and inhibits HNF1β-dependent transcription**

To investigate the molecular mechanism explaining the differentiation defects observed at the progenitor stage in HNF1α-MODY3 and HNF1αCRISPR lines, we performed bulk RNA-sequencing analysis of HNF1αWT and HNF1αCRISPR PPs. Samples within the subgroups clustered closely together by transcriptome analysis (Figure S6A), and HNF1αCRISPR lines showed a decreased enrichment score for β cell gene signature compared with HNF1αWT lines (Figure S6B). Interestingly, among the top 50 differentially expressed genes in HNF1αCRISPR versus HNF1αWT progenitors we found downregulation of PKHD1 and KIF12 (Figure S6C), both previously described HNF1α targets, but also reported as affected by HNF1α knockout (Servitja et al., 2009; Chan et al., 2018), supporting a potential homo-/heterodimer dynamic (Figure 5A). HNF1α and HNF1β form homodimers and heterodimers to regulate gene transcription in liver, pancreas, and kidney (Lau et al., 2018) and HNF1β mutations in MODY5 patients leads to severe diabetes (Horikawa, 2018), in part due to the fundamental role of HNF1β in early pancreatic morphogenesis (De Vas et al., 2015; El-Khairi and Valleri, 2016). We hypothesized that HNF1αp291fsinsC could alter the HNF1α-HNF1β balance to affect HNF1α and HNF1β target genes and contribute to the PP differentiation defect observed in HNF1α-MODY3 and HNF1αCRISPR lines. We found 16 HNF1β target genes described in the literature (Chan et al., 2018; Matsui et al., 2016; Verhave et al., 2016), of which some are involved in Wnt and Notch signaling, and 19 HNF1α-specific targets, as described by Servitja et al. (2009), within the significantly dysregulated genes comparing HNF1αCRISPR and HNF1αWT datasets (Figures 5B, 5C, and S6D). Since the HNF1αp291fsinsC mutation affected both HNF1α and HNF1β target genes, we generated lentiviral-based constructs to overexpress FLAG- or myc-tagged versions of HNF1αWT, HNF1αp291fsinsC (HNF1αMUT), and HNF1β (Figure 5D) in HEK293T cells and tested for biochemical interactions. While overexpressed HNF1β and HNF1αWT subcellular localization was mainly nuclear, overexpressed HNF1αMUT was present in the cytoplasmic and nuclear fraction and not affected by HNF1β (Figures 5E and S5F), HNF1β efficiently pulled down HNF1αWT and HNF1αMUT in cells co-transfected with HNF1αWT/HNF1β or HNF1αMUT/HNF1β (Figure 5G).

Since overexpression of HNF1αMUT together with HNF1β or HNF1αWT did not affect HNF1β protein stability measured after a cycloheximide chase (Figures S6E and S6F), HNF1β localization (Figure S6G), or HNF1αWT levels (Figure S6H), we hypothesized that HNF1αMUT could affect HNF1β transcriptional activity by interacting with HNF1β, reducing its ability to homodimerize. To test this hypothesis, we introduced the previously described L12H mutation in the HNF1αMUT dimerization domain (HNF1αL12H/MUT) (Narayana et al., 2001) (Figure 5H) and analyzed whether this hampers its interaction with HNF1β (Figure 5I). While HNF1αMUT efficiently interacted with HNF1β, the L12H mutation in HNF1αL12H/MUT was sufficient to abolish its interaction with HNF1β (Figure 5I). Accordingly, HNF1β overexpression in HEK293T cells did not change the subcellular localization of HNF1αL12H/MUT protein, which was mainly observed in the cytoplasm (Figure S7A).

The interaction of HNF1αp291fsinsC and HNF1β proteins could also be detected in patient-derived HNF1α-MODY3 PP organoids (Figure S5J). Interestingly, overexpressing HNF1αMUT in HNF1αWT PP organoids led to a reduction of the HNF1β target genes PKHDI, KIF12, and JAG1 (Figures 5K, S7B, and S7C). However, overexpressing the HNF1αL12H/MUT dimerization mutant in HNF1αWT PP organoids did not result in a significant difference in the expression of the HNF1β target genes PKHD1, KIF12, and JAG1 (Figures 5K, S7B, and S7C), suggesting that the dimerization of HNF1αp291fsinsC and HNF1β is required for the impairment of HNF1β-dependent transcription observed in HNF1α-MODY3 PPs. To assess the effect of the HNF1αMUT protein on HNF1β binding to the PKHD1 promoter, we performed chromatin immunoprecipitation in cells overexpressing HNF1β, HNF1β-HNF1αWT, or HNF1α-HNF1αMUT proteins (Figure S7D), using SATz promoter as a negative control (Figure S7D). We observed that HNF1β efficiently binds to the PKHD1 promoter, and this is enhanced in presence of HNF1αWT (Figure S7D). Interestingly, HNF1β binding to PKHD1 promoter was reduced to baseline levels in the presence of HNF1αMUT (Figure S7D), indicating that the p291fsinsC mutation in the HNF1αMUT protein could impair the binding of both HNF1β-HNF1β homodimers and HNF1β-HNF1α heterodimers to target genes such as PDKH1.

Consistent with the effect of the p291fsinsC mutation on both HNF1α- and HNF1β-dependent transactivation and impaired progenitor and β cell phenotype, we further tested whether overexpression of HNF1α or HNF1β using lentivirus transduction would be sufficient to rescue the PP phenotype observed in HNF1α-MODY3 lines (Figure 6). First, we transduced PP organoids derived from one HNF1αMODY3 line with either HNF1α-GFP lentivirus or HNF1β-GFP lentivirus or HNF1α-mCherry lentivirus (Figure 6A) and investigated PDX1 expression after PP differentiation. Efficient overexpression of HNF1α-GFP or HNF1β-mCherry protein was detected by immunofluorescence and flow cytometry analysis in the transduced HNF1αMODY3 organoid line (Figures 6B and 6C). Although a partial increase in the percentage of PDX1+ progenitors was observed in the HNF1αMODY3 line overexpressing HNF1α-GFP or HNF1β-mCherry, only HNF1β-mCherry overexpression led to a significant rescue in the percentage and area of PDX1+ cells in the HNF1αMODY3 line (Figures 6D and 6E). We further investigated whether HNF1α-GFP or HNF1β-mCherry overexpression was sufficient to rescue the impaired β cell differentiation phenotype observed in HNF1αMODY3 lines. To achieve this, we transduced iPSCs with either HNF1α-GFP or HNF1β-mCherry overexpressing lentivirus, generated PP progenitor organoids from the transduced cells, and differentiated them toward islet-like cells (Figure 7A). Consistent with the PDX1+ progenitor rescue observed in HNF1β-mCherry overexpressing organoids (Figures 6D and 6E), we detected a significant increase in INS+, SST+, and GCG+ in HNF1β-mCherry overexpressing cells after differentiation when compared with the HNF1αMODY3 line (Figures 7B and 7C). Altogether, these data confirm that the interaction of HNF1αp291fsinsC with HNF1β...
Figure 5. HNF1α p291fsinsC truncated protein interacts with HNF1β and impairs HNF1β-dependent transcription

(A) Volcano plot of significantly differentially expressed genes in HNF1αWT versus HNF1αCRISPR PPs. PKHD1 and KIF12 are indicated.
(B) Heatmap of differentially expressed HNF1β targets in HNF1αWT/HNF1αCRISPR PPs.
(C) qRT-PCR analysis of HNF1β target genes PKHD1, KIF12, TWIST1, and WNT5A. n = 3 independent differentiations.
(D) Schematic depicting the constructs used for overexpression of HNF1αWT/HNF1αMUT and HNF1β proteins.
(E) IF analysis on HNF1α/HNF1β transfected HEK293T cells.
(F) Nuclear/cytoplasmic HNF1α fluorescence intensity quantification in HEK293 transfected with HNF1αWT/HNF1αMUT and HNF1β proteins.
(G) FLAG immunoprecipitation in HNF1α/HNF1β transfected HEK293T cells. Vinculin, HNF1β, and HNF1α were detected by immunoblot in the input and immunoprecipitation (IP). n = 3 independent experiments.
(H) Schematic depicting the constructs used for HNF1αMUT/HNF1αL12H/MUT overexpression. Red asterisk depicts the point mutation L12H known to affect HNF1α dimerization domain.
(I) FLAG immunoprecipitation in HNF1α/HNF1β transfected HEK293T cells. Vinculin, HNF1β, and HNF1α were detected by immunoblot in the input and IP. n = 3 independent experiments.
(J) HNF1β immunoprecipitation in HNF1αWT/HNF1αMODY3 PP organoids. HNF1β and HNF1α were detected by immunoblot in the input and IP. Asterisks indicate the specific bands for HNF1β and HNF1α. Red asterisk indicates truncated mutated form of HNF1α.
(K) qRT-PCR analysis of HNF1β target genes PKHD1, KIF12, JAG1, and WNT5A in HNF1αWT organoids transfected with HNF1αMUT/HNF1αL12H/MUT proteins. n = 3–4 independent experiments.

Error bars are SEM. p values shown only for significant differences determined by one-way ANOVA followed by Tukey’s multiple comparison test (C, F, and K). Scale bars, 100 μm (E) and 50 μm (E, insets). See also Figures S6 and S7.
greatly contributes to the progenitor and β cell differentiation defect observed in MODY3 patient iPSC lines.

**DISCUSSION**

HNF1α<sup>p291fsinsC</sup> mutation results in MODY3 diabetes onset with variable penetrance and is mostly diagnosed before 25 years of age (Lebenthal et al., 2018; Urakami, 2019). So far, there has been only limited success in using hiPSCs to understand MODY3 disease mechanisms (Yabe et al., 2019). Interestingly, loss of HNF1α in genetically engineered ESCs shows decreased insulin secretion, glycolysis, mitochondrial function, and developmental bias toward α cells upon differentiation (Cardenas-Diaz et al., 2019). However, whether the complete or partial loss of HNF1α in ESCs recapitulates the most frequent mutation in MODY3 (HNF1α<sup>p291fsinsC</sup>) is not clear.

In this study, by using hiPSCs from healthy donors, MODY3 patients, and CRISPR/Cas9-engineered lines, we have uncovered progenitor and β cell differentiation defects caused by the HNF1α<sup>p291fsinsC</sup> mutation. Human ESCs lacking both HNF1α alleles develop normally into β cells, with a slight decrease in β cell number and significant downregulation of PDX1 (Cardenas-Diaz et al., 2019). However, our data suggest that the additional HNF1α<sup>p291fsinsC</sup> dominant negative function over HNF1β accounts for a more severe phenotype not comparable with HNF1α loss, with both HNF1α and HNF1β target genes being affected. Consistently, the HNF1α/HNF1β target genes PKHD1 and KIF12, whose malfunction is associated with developmental defects (Bergmann et al., 2005; Kalantari and Filges, 2020), as well as HNF1β-related components of the Wnt and Notch pathways (Chan et al., 2018) important for early pancreatic development, were downregulated in HNF1α<sup>p291fsinsC</sup> lines (Figure 5).

Our data suggest that by dimerizing with HNF1β, HNF1α<sup>p291fsinsC</sup> inhibits HNF1β-dependent transcription and PP differentiation. The severe phenotype observed in the HNF1α<sup>MODY3</sup> lines is in agreement with previous findings of an earlier onset for patients harboring truncating mutations (Bellanne-Chantelot et al., 2008) and the progressive β cell failure observed in patients over time (Frayling et al., 2001). Though consistently observed, the degree of PP differentiation defect varied among the five patient lines and was associated with the clinical symptoms in these patients, with multiple complications (Figure S2A) and diverse genetic backgrounds contributing to more severe phenotypes (Hattersley, 1998; Lebenthal et al., 2018). Our findings suggest that this heterogeneity could be explained by the antagonizing effect of HNF1α<sup>p291fsinsC</sup> on HNF1β function (Figure 5). The partial β cell rescue upon overexpression of HNF1β in HNF1α<sup>p291fsinsC</sup> organoids (Figure 7) implies that HNF1β levels in each patient line...
could account for the heterogeneity observed and explain distinct MODY3 phenotypes.

Organoid models for progenitor expansion have been developed from mouse and human adult tissue (Huch et al., 2013; Looijmans et al., 2018) and hESCs (Bakhti et al., 2019), but have not yet been developed from hiPSCs to model diabetes. Here, we developed an efficient method to expand progenitors from hiPSCs and differentiate them toward β-like cells. By using healthy, MODY3, and CRISPR/Cas9 hiPSC-derived PP organoids, we observed that HNF1αp291fsinsC affects the formation of β-like cells in a relevant human model through a previously undescribed mechanism, with similar phenotypes also observed in mice and pig models of MODY3 (Hagenfeldt-Johansson et al., 2001; Umeyama et al., 2017; Yamagata et al., 2002). Accordingly, patients with HNF1αp291fsinsC mutation display pancreatic abnormalities, with a smaller pancreas size and β cell mass (Sanyoura et al., 2018; Vesterhus et al., 2008), consistent with our results showing a reduced progenitor pool derived from mutant iPSCs known to be a crucial limiting factor for pancreas size and β cell mass (Stanger et al., 2007). In summary, our study identifies a new mechanism by which the truncated HNF1αp291fsinsC protein arising from the common MODY3 p291fsinsC mutation abrogates HNF1β function and impairs PP and β cell development. Additionally, our PP organoid system represents an ideal platform from which to investigate pancreatic developmental defects associated with monogenic diabetes.

**Limitations of the study**

Although the number of MODY3 hiPSC lines used in this study was reduced due to the intrinsic difficulty in obtaining hiPSCs from patients with rare diseases, the phenotype was consistent in most patient lines and in the CRISPR/Cas9-engineered lines, allowing us to confidently uncover novel mechanisms of HNF1αp291fsinsC mutation on β cell development. Our in vitro model of pancreatic development is reductionist compared with the in vivo counterpart tissue, due to absence of exocrine, ductal tissue, and vascularization. In the future, more complex organoid systems that comprise multiple cell types could be used to investigate MODY3 in more physiologically complete models.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
Supplemental information can be found online at https://doi.org/10.1016/j.celrep.2022.110425.

Acknowledgments

We thank Francesca Spagnoli and Anne Grapin-Botton for critical reading of the manuscript and Franco Fraternali for sharing discussions about the genomic analysis. We thank Davide Danovi for access to HipSci lines. A.-M.C. is supported by a Wellcome Trust PhD fellowship (108874/Z/15/Z). We worked to ensure diversity in experimental samples through the selection of the cell lines. We worked to ensure diversity in experimental samples through the selection of the genomic datasets. One or more of the authors of this paper self-identifies as a member of the LGBTQ+ community.

Inclusion and Diversity

Received: March 26, 2021
Revised: September 23, 2021
Accepted: February 2, 2022
Published: March 1, 2022

References

Andrews, S. (2010). FastQC: A Quality Control Tool for High Throughput Sequence Data, http://www.bioinformatics.babraham.ac.uk/projects/fastqc/.

Assou, S., Girault, N., Plinet, M., Bouckenheimer, J., Sansac, C., Combe, M., Mianne, J., Bourguignon, C., Fieldes, M., Ahmed, E., et al. (2020). Recurrent genetic abnormalities in human pluripotent stem cells: definition and routine detection in culture supernatant by targeted droplet digital PCR. Steril Cell Rep, 7, 1–48.

Bakht, M., Scheibner, K., Tritschler, S., Bastidas-Ponce, A., Tarquis-Medina, M., Theia, F.J., and Lickert, H. (2019). Establishment of a high-resolution 3D modeling system for studying pancreatic epithelial cell biology in vitro. Mol. Metab. 30, 16–29.

Balamurugan, K., Bjorkhaug, L., Mahajan, S., Kanthimathi, S., Njolstad, P.R., Srinivasan, M., Mohan, V., and Radha, V. (2016). Structure-function studies of HNF1A (MODY3) gene mutations in South Indian patients with monogenic diabetes. Clin. Genet. 90, 486–495.

Belanne-Chantelot, E., Carette, C., Reline, J.P., Valero, R., Gautier, J.F., Larger, E., Reznik, Y., Duculzeau, P.H., Sola, A., Hartemann-Heurtier, A., et al. (2008). The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3. Diabetes 57, 503–508.

Bergmann, C., Senderek, J., Windelen, E., Kupper, F., Middeldorf, I., Schneider, F., Dornia, C., Rudnik-Schoneborn, S., Konrad, M., Schmitt, C.P., et al. (2005). Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD). Kidney Int. 67, 829–848.

Bockenhauer, D., and Jaureguiberry, G. (2016). HNF1B-associated clinical phenotypes: the kidney and beyond. Pediatr. Nephrol. 31, 707–714.

Bolger, A.M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120.

Bolognini, R., and Nobili, V. (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120.

Cardenas-Diaz, F.L., Osorio-Quintero, C., Diaz-Miranda, M.A., Kishore, S., Leavens, K., Jobalayi, C., Stanescu, D., Ortiz-Gonzalez, K., Yoon, C., Chen, C.S., et al. (2019). Modeling monogenic diabetes using human ESCs reveals developmental and metabolic deficiencies caused by mutations in HNF1A. Cell Stem Cell 25, 273–289.e5.

Cereghini, S., Ott, M.O., Power, S., and Maury, M. (1992). Expression patterns of vHNF1 and HNF1 homeoproteins in early postimplantation embryos suggest distinct and sequential developmental roles. Development 116, 783–797.

Chan, S.C., Zhang, Y., Shao, A., Avdulov, S., Herrera, J., Aboudehen, K., Pong-Toglio, M., and Igarashi, P. (2018). Mechanism of fibrosis in HNF1B-related autosomal dominant tubulo-interstitial kidney disease. J. Am. Soc. Nephrol. 29, 2490–2509.

Cubuk, H., and Yalcin Capan, O. (2021). A review of functional characterization of single amino acid change mutations in HNF transcription factors in MODY pathogenesis. Protein J. 40, 348–360.
De Vas, M.G., Kopp, J.L., Heliot, C., Sander, M., Cereghini, S., and Haumaitre, C. (2015). Hnf1b controls pancreas morphogenesis and the generation of Ngn3+ endocrine progenitors. Development 142, 871–882.

Dobin, A., and Gingeras, T.R. (2015). Mapping RNA-seq reads with STAR. Curr. Protoc. Bioinformatics 51/10, 11 14 11 14 19.

El-Khairi, R., and Vallier, L. (2016). The role of hepatocyte nuclear factor 1beta in disease and development. Diabetes Obes. Metab. 18, 23–32.

Ellard, S., and Colclough, K. (2006). Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young. Hum. Mutat. 27, 854–869.

Frayling, T.M., Bulman, M.P., Ellard, S., Appleton, M., Dronsfield, M.J., Mackie, A.D., Baird, J.D., Kaisaki, P.J., Yamagata, K., Bell, G.I., et al. (1997). Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U.K. Diabetes 46, 720–725.

Frayling, T.M., Evans, J.C., Bulman, M.P., Pearson, E., Allen, L., Owen, K., Bingham, C., Hannemann, M., Shepherd, M., Ellard, S., et al. (2001). beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors. Diabetes 50, S94–S100.

Hagemann-Matthaei, K.A., Herrero, P.L., Wang, H., Gjinovci, A., Ishihara, H., and Wolffheim, G.B. (2001). Beta-cell-targeted expression of a dominant-negative hepatocyte nuclear factor-1 alpha induces a maturity-onset diabetes of the young (MODY3-like phenotype in transgenic mice. Endocrinology 142, 5311–5320.

Harries, L.W., Hattersley, A.T., and Ellard, S. (2004). Messenger RNA transcripts of the hepatocyte nuclear factor-1alpha gene containing premature termination codons are subject to nonsense-mediated decay. Diabetes 53, 500–504.

Hattersley, A.T. (1998). Maturity-onset diabetes of the young: clinical heterogeneity explained by genetic heterogeneity. Diabet Med. 15, 15–24.

Horikawa, Y. (2018). Maturity-onset diabetes of the young as a model for elucidating the multifactorial origin of type 2 diabetes mellitus. J. Diabetes Investig. 9, 704–712.

Howie, B.N., Donnelly, P., and Marchini, J. (2009). A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. Plos Genet. 5, e1000529.

Huch, M., Bonfanti, P., Boj, S.F., Sato, T., Loomans, C.J., van de Wetering, M., Sojojodi, M., Li, V.S., Schuijers, J., Gracanin, A., et al. (2013). Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis. EMBO J. 32, 2708–2721.

Kaisaki, P.J., Menzel, S., Lindner, T., Oda, N., Rjasanowski, I., Sahm, J., Meinecke, G., Schulze, J., Schmehel, H., Petzold, C., et al. (1997). Mutations in the hepatocyte nuclear factor-1alpha gene in MODY and early-onset NIDDM: evidence for a mutational hotspot in exon 4. Diabetes 46, 529–535.

Kalantari, S., and Filges, I. (2020). Kinesinopathies: emerging role of the kinesin family member genes in birth defects. J. Med. Genet. 57, 985–996.

Kishimoto, T., Wang, Y., Kajimura, S., and Watanabe, M. (2015). HNF1b controls pancreas morphogenesis and the generation of Ngn3+ endocrine progenitors. Development 142, 23–32.

Lee, Y.H., Sauer, B., and Gonzalez, F.J. (1998). Laron dwarfism and non-insulin-dependent diabetes mellitus in the Hnf-1alpha knockout mouse. Mol. Cell Biol. 18, 3059–3068.

Lehto, M., Tuomi, T., Mahtani, M.M., Widen, E., Forsblom, C., Sarelin, L., Gullstrom, M., Isomaa, B., Lehtovirta, M., Hyrkkko, A., et al. (1997). Characterization of the MODY3 phenotype. Early-onset diabetes caused by an insulin secretion defect. J. Clin. Invest. 99, 582–591.

Liao, Y., Smyth, G.K., and Shi, W. (2013). The Subread aligner: fast, accurate and scalable read mapping by seed-and-extend. Nucleic Acids Res. 41, e108.

Lokmane, L., Haumaitre, C., Garcia-Villalba, P., Anselme, I., Schneider-Maunoury, S., and Cereghini, S. (2008). Crucial role of vHNF1 in vertebrate hepatic specification. Development 135, 2777–2786.

Loomans, C.J.M., Williams Giulian, N., Balak, J., Ringnald, F., van Gurp, L., Huch, M., Boj, S.F., Sato, T., Kester, L., de Sousa Lopes, S.M.C., et al. (2018). Expansion of adult human pancreatic tissue yields organoids harboring progenitor cells with endocrine differentiation potential. Stem Cell Rep. 10, 712–724.

Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550.

Matsui, A., Fujimoto, J., Ishikawa, K., Ito, E., Goshima, N., Watanabe, S., and Semb, K. (2016). Hepatocyte nuclear factor 1 beta induces transformation and epithelial-to-mesenchymal transition. FEBS Lett. 590, 1211–1221.

McCaugh, E.C., and Nostro, M.C. (2017). Efficient differentiation of pluripotent stem cells to NK6-1+ pancreatic progenitors. J. Vis. Exp. (121), 55265.

Mendel, D.B., Hansen, L.P., Graves, M.K., Conley, P.O., and Crabtree, G.R. (1991). HNF-1 alpha and HNF-1 beta (vHNF-1) share dimerization and hormone domains, but not activation domains, and form heterodimers in vitro. Genes Dev. 5, 1042–1056.

Narayana, N., Hua, Q., and Weiss, M.A. (2001). The dimerization domain of HNF-1alpha: structure and plasticity of an intertwined four-helix bundle with application to diabetes mellitus. J. Mol. Biol. 310, 635–658.

Oikka, K., Yang, Q., Yamagata, K., Hangenfeld, K.A., Miyagawa, J., Kajimoto, Y., Nakajima, H., Namba, M., Wolffheim, C.B., Hanafusa, T., et al. (1999). Human insulin gene is a target gene of hepatocyte nuclear factor-1alpha (HNF-1alpha) and HNF-1beta. Biochem. Biophys. Res. Commun. 263, 556–569.

Pearson, E.R., Liddell, W.G., Shepherd, M., Corrall, R.J., and Hattersley, A.T. (2000). Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med. 17, 543–545.

Pontoglio, M., Barra, J., Hadchouel, M., Doyen, A., Kress, C., Bach, J.P., Babinet, C., and Yaniv, M. (1996). Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal fanconi syndrome. Cell 84, 575–585.

Pontoglio, M., Sreenan, S., Roe, M., Pugh, W., Ostrega, D., Doyen, A., Pick, A.J., Baldwin, A., Velho, G., Froguel, P., et al. (1998). Defective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice. J. Clin. Invest. 101, 2215–2222.

Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308.

Rebuzzini, P., Zuccotti, M., Redi, C.A., and Garagna, S. (2015). Chromosomal abnormalities in embryonic and somatic stem cells. Cytogenet. Genome Res. 147, 1–9.

Rey-Campos, J., Chouard, T., Yaniv, M., and Cereghini, S. (1991). vHNF1 is a homeoprotein that activates transcription and forms heterodimers with HNF1. EMBO J. 10, 1445–1457.

Rogers, G.J., Hodgkin, M.N., and Squires, P.E. (2007). E-cadherin and cell adhesion: a role in architecture and function in the pancreatic islet. Cell Physiol. Biochem. 20, 987–994.
of human pancreatic progenitors produces functional beta-like cells in vitro. EMBO J. 34, 1759–1772.

Sanyoura, M., Jacobsen, L., Carmody, D., Del Gaudio, D., Alkorta-Aranburu, G., Arndt, K., Hu, Y., Kobiernicki, F., Kusmartseva, I., Atkinson, M.A., et al. (2018). Pancreatic histopathology of human monogenic diabetes due to causal variants in KCNJ11, HNF1A, GATA6, and LMNA. J. Clin. Endocrinol. Metab. 103, 35–45.

Schneider, C., Rasband, W., and Eliceiri, K. (2012). NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675.

Servitja, J.M., Pignotelli, M., Maestro, M.A., Cardaleta, D., Boj, S.F., Lozano, J., Blanco, E., Lafuente, A., McCarthy, M.I., Sumoy, L., et al. (2009). Hnf1alpha (MODY3) controls tissue-specific transcriptional programs and exerts opposed effects on cell growth in pancreatic islets and liver. Mol. Cell. Biol. 29, 2945–2959.

Stanger, B.Z., Tanaka, A.J., and Melton, D.A. (2007). Organ size is limited by the number of embryonic progenitor cells in the pancreas but not the liver. Nature 445, 886–891.

Stepniowski, J., Kachamakova-Trojanowska, N., Ogrecki, D., Szopa, M., Matlok, M., Belitarz, M., Dyduch, G., Malecki, M.T., Jozkowicz, A., and Dulak, J. (2015). Induced pluripotent stem cells as a model for diabetes investigation. Sci. Rep. 5, 8597.

Streeter, I., Harrison, P.W., Faulconbridge, A., The HipSci, C., Flicek, P., Parkinson, H., and Clarke, L. (2017). The human-induced pluripotent stem cell initiative-data resources for cellular genetics. Nucleic Acids Res. 45, D691–D697.

Stride, A., Shepherd, M., Frayling, T.M., Bulman, M.P., Ellard, S., and Hattersley, A.T. (2002). Intrauterine hyperglycemia is associated with an earlier diagnosis of diabetes in HNF-1alpha gene mutation carriers. Diabetes Care 25, 2287–2291.

Trott, J., Tan, E.K., Ong, S., Titmarsh, D.M., Denil, S., Giann, M., Wong, C.K., Wang, J., Shboul, M., Eio, M., et al. (2017). Long-term culture of self-renewing pancreatic progenitors derived from human pluripotent stem cells. Stem Cell Rep. 8, 1675–1688.

Truchan, N.A., Brar, H.K., Gallagher, S.J., Neuman, J.C., and Kimple, M.E. (2015). A single-islet microplate assay to measure mouse and human islet insulin secretion. Islets 7, e1076607.

Umezawa, K., Nakajima, M., Yokoo, T., Nagaya, M., and Nagashima, H. (2017). Diabetic phenotype of transgenic pigs introduced by dominant-negative mutant hepatocyte nuclear factor 1alpha. J. Diabetes Complications 31, 796–803.

Urakami, T. (2019). Maturity-onset diabetes of the young (MODY): current perspectives on diagnosis and treatment. Diabetes Metab. Syndr. Obes. 12, 1047–1056.

Valkovicova, T., Skopkova, M., Stanik, J., and Gasperikova, D. (2019). Novel insights into genetics and clinics of the HNF1A-MODY. Endocr. Regul. 53, 110–134.

Vaxillaire, M., Abderrahmani, A., Boutin, P., Bailleul, B., Froguel, P., Yaniv, M., and Pontoglio, M. (1999). Anatomy of a homeoprotein revealed by the analysis of human MODY3 mutations. J. Biol. Chem. 274, 35639–35646.

Verhave, J.C., Bech, A.P., Wetzels, J.F., and Nijenhuis, T. (2016). Hepatocyte nuclear factor 1beta-associated kidney disease: more than renal cysts and diabetes. J. Am. Soc. Nephrol. 27, 345–353.

Vesterhus, M., Haldorsen, I.S., Raeder, H., Molven, A., and Njolstad, P.R. (2008). Reduced pancreatic volume in hepatocyte nuclear factor 1A-maturity-onset diabetes of the young. J. Clin. Endocrinol. Metab. 93, 3505–3509.

Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164.

Yabe, S.G., Iwasaki, N., Yasuda, K., Hamazaki, T.S., Konno, M., Fukuda, S., Takeda, F., Kasuga, M., and Okochi, H. (2015). Establishment of maturity-onset diabetes of the young-induced pluripotent stem cells from a Japanese patient. J. Diabetes Investig. 6, 543–547.

Yabe, S.G., Nishida, J., Fukuda, S., Takeda, F., Naisiro, K., Yasuda, K., Iwasaki, N., and Okochi, H. (2019). Expression of mutant mRNA and protein in pancreatic cells derived from MODY3-iPS cells. PLoS One 14, e0217110.

Yamagata, K., Nanno, T., Moriwaki, M., Ibara, A., Izuoka, K., Yang, G., Satoh, T., Li, M., Uenaka, R., Okita, K., et al. (2002). Overexpression of dominant-negative mutant hepatocyte nuclear factor-1 alpha in pancreatic beta-cells causes abnormal islet architecture with decreased expression of E-cadherin, reduced beta-cell proliferation, and diabetes. Diabetes 51, 114–123.

Yamagata, K., Oda, N., Kaisaki, P.J., Menzel, S., Furuta, H., Vaxillaire, M., Southam, L., Cox, R.D., Lathrop, G.M., Boriraj, V.V., et al. (1996). Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 384, 455–458.

Yamagata, K., Yang, Q., Yamamoto, K., Ishii, H., Miyagawa, J., Okita, K., Yoshiiuchi, I., Miyazaki, J., Naguchi, T., Nakajima, H., et al. (1998). Mutation P291insC in the transcription factor hepatocyte nuclear factor-1alpha is dominant negative. Diabetes 47, 1231–1235.
### STAR METHODS

#### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| Goat anti-SOX17     | R&D    | Cat#AF1924; RRID: AB_355060 |
| Mouse anti-OCT4     | Santa Cruz | Cat#sc-5279; RRID: AB_628051 |
| Rabbit anti-NANOG   | CST    | Cat#4903S; RRID: AB_1059205 |
| Rabbit anti-HNF1A   | CST    | Cat#D7Z2Q; RRID: AB_2728751 |
| Goat anti-HNF1B     | Invitrogen | Cat#PAS-18642; RRID: AB_10983492 |
| Rabbit anti-HNF1B   | Invitrogen | Cat#720259; RRID: AB_2633221 |
| Rabbit anti-PDX1    | Cell Signalling | Cat#5679; RRID: AB_10706174 |
| Guinea pig anti-PDX1| Abcam | Cat#abf47308; RRID: AB_777178 |
| Mouse anti-NKX6.1   | DSHB   | Cat#F55A12; RRID: AB_532379 |
| Mouse anti-NKX6.1   | DSHB   | Cat#F55A10; RRID: AB_532378 |
| Goat anti-SOX9      | R&D    | Cat#AF3075; RRID: AB_2194160 |
| Guinea pig anti-insulin | DAKO | Cat#A0564; RRID: AB_10013624 |
| Rabbit anti-somatostatin | DAKO | Cat#A0566; RRID: AB_2688022 |
| Mouse anti-glucagon | abcam | Cat#abf10988; RRID: AB_297642 |
| Mouse Ki67          | Cell Signalling | Cat#ab9449S; RRID: AB_2797703 |
| Mouse CXCR4-A647    | BD     | Cat#555976; RRID: AB_398616 |
| Rat anti-CK19       | DSHB   | Cat#TROMA IIc 10ea; RRID: AB_2133570 |
| Rabbit anti-insulin | abcam | Cat#abf63820; RRID: AB_1925116 |
| Mouse anti-E-cadherin | Cell Signalling | Cat#14472S; RRID: AB_2728770 |
| Rabbit anti-ZO-1    | Invitrogen | Cat#40-2200; RRID: AB_2533456 |
| Donkey anti-mouse Alexa 647 | Invitrogen | Cat#A31571; RRID: AB_162542 |
| Donkey anti-rabbit Alexa 488 | Invitrogen | Cat#A21206; RRID: AB_2535792 |
| Donkey anti-goat Alexa 555 | Invitrogen | Cat#A21432; RRID: AB_2535853 |
| Donkey anti-rabbit Alexa 555 | Invitrogen | Cat#A31572; RRID: AB_162543 |
| Donkey anti-goat Alexa 647 | Invitrogen | Cat#A21447; RRID: AB_141844 |
| Donkey anti-mouse Alexa 488 | Invitrogen | Cat#A21202; RRID: AB_141607 |
| Goat anti-guinea pig Alexa 488 | Invitrogen | Cat#A11073; RRID: AB_2534117 |
| Donkey anti-rat Alexa 647 | Invitrogen | Cat#A21472; RRID: AB_1500700 |
| Mouse PDX1-A488     | BD     | Cat#562274; RRID: AB_10924596 |
| Mouse NKX6.1-A647   | BD     | Cat#563338; RRID: AB_2738144 |
| Mouse ik67-A647     | BD     | Cat#558615; RRID: AB_647130 |
| A488 IgG1k isotype control | BD | Cat#557721; RRID: AB_396830 |
| A647 IgG1k isotype control | BD | Cat#557714; RRID: AB_396823 |
| Anti-Flag           | Sigma-Aldrich | Cat#M8823; RRID: AB_2637089 |
| Goat anti-Rabbit HRP | Jackson ImmunoResearch | Cat#111-035-144; RRID: AB_2307391 |
| Donkey anti-Goat HRP | Jackson ImmunoResearch | Cat#705-035-147; RRID: AB_2313587 |
| Goat anti-Mouse HRP | Jackson ImmunoResearch | Cat#115-035-146; RRID: AB_2307392 |

### Bacterial and virus strains

- One Shot® TOP10 Competent Cells | Thermo Fisher | C404010 |

### Chemicals, peptides, and recombinant proteins

- Bovine Serum Albumin | Sigma | A1470-100G |
- Triton X-100 | Sigma | T9284-1L |
- PFA 4% | Alfa-Aesar | J19943 |

(Continued on next page)
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Tween 20            | Sigma  | P1379      |
| Glycine             | Sigma  | G7126      |
| Ethylenediaminetetraacetic acid (EDTA) | Fisher BioReagents | BP2482-500 |
| Accutase            | BioLegend | 423201  |
| Power SYBR Green Master Mix | ThermoFisher | 4385614 |
| DAPI (5 mg/ml stock) | Invitrogen | D1306     |
| OCT Embedding Matrix | Fisher   | 361603E    |
| Cytofix™ Fixation buffer | BD      | 554655     |
| Pharmingen™ Stain Buffer (FBS) | BD      | 554656     |
| Phosflow™ Permeabilization Buffer III | BD      | 558050     |
| Matrigel® Growth Factor Reduced (GFR) | Corning | 354230     |
| Basement Membrane Matrix |         |            |
| Vitronectin         | Stem Cell Technologies | 7180      |
| HEPES               | ThermoFisher | 15630080  |
| Glutamax supplement | ThermoFisher | 3505006   |
| Penicillin/Streptomycin | ThermoFisher | 15140122  |
| A83-01              | TOCRIS  | 2939       |
| Human FGF-10        | Peprotech | 100-26     |
| Gastrin             | Sigma   | SCP0151    |
| Mouse EGF           | Peprotech | AF10015    |
| N-acetylcysteine    | Sigma-Aldrich | A9165   |
| Nicotinamide        | Sigma-Aldrich | N0636-100G |
| B27 supplement      | Thermo Fisher | 17504044  |
| Noggin-conditioned-media | This study | N/A       |
| R-spondin-conditioned-media | This study | N/A       |
| Y-27631             | Adooq Bioscience | A11001    |
| TryplE              | ThermoFisher | 12604021  |
| Retinoic acid       | Sigma   | R2625-50MG |
| LDN-193189          | Stemgent | 04-0074   |
| TBP                 | Millipore | 565740-1MG |
| ALKII               | Axxora   | ALX-270-445-M001 |
| NEAA                | Gibco   | 11140035   |
| FGF7                | R&D Systems | 251-KG-010 |
| Ampicillin          | Sigma Aldrich | A9518-25G |
| Dimethyl sulfoxide (DMSO) | Sigma | D2650-100ML |
| Proteinase K        | VWR     | A380,0025  |
| Q5 high-fidelity DNA polymerase | NEB | M0491L |
| Polyethyleneimine (PEI) | Sigma Aldrich | 408727 |
| IGEPAL (Nonidet-P40 (NP-40) substitute) | Sigma-Aldrich | 18896 |
| NaF                 | NEB     | P0759      |
| Phenylmethylsulfonyl fluoride (PMSF) | Sigma-Aldrich | PMSF-RO |
| Orthovanadate       | NEB     | P0758      |
| Protease inhibitor cocktail | Sigma-Aldrich | P8340-5ML |
| Laemmli buffer 4x   | Genetex | GTX16355   |
| TBS-Tween 20% 20x   | Severn  | 20-7310-10 |
| Polybrene           | Merck   | TR-1003-G  |
| Lenti-X concentrator | Takara bio | 631232    |
| Chelex-100          | Biorad  | 142-1253   |
### REAGENT or RESOURCE SOURCE IDENTIFIER

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Pierce™ ChIP grade protein A/G Magnetic beads | Thermo Scientific | 26162 |
| Pierce™ protein A/G Magnetic beads | Thermo Scientific | 88803 |

### Critical commercial assays

| RESOURCE | SOURCE | IDENTIFIER |
|----------|--------|------------|
| RNeasy mini kit | Qiagen | 74106 |
| QuantiTect Reverse transcription kit | Qiagen | 203314 |
| Spin MiniPrep kit | Qiagen | 27106 |
| Spin Midiprep kit | Qiagen | 12145 |
| Lipofectamine™ 3000 Transfection Reagent | Thermo Fisher | L3000001 |
| Monarch PCR-cleaning kit | NEB | T10305 |
| CXCR4 MicroBead Kit | Miltenyi Biotec | 130-100-070 |
| MACS LS Columns | Miltenyi Biotec | 130-042-401 |
| DirectPCR Lysis Reagent (Cell) | Viagen Biotech | 301-C |
| Bradford assay | Biorad | 500006 |

### Deposited data

- Raw and count files have been deposited in NCBI’s Gene Expression Omnibus. [GEO: GSE166822](https://www.ncbi.nlm.nih.gov/geo/)
- All original code has been deposited at Zenodo and is publicly available as of the date of publication. [Zenodo: https://doi.org/10.5281/zenodo.5834882](https://doi.org/10.5281/zenodo.5834882)

### Experimental models: Cell lines

| EXPERIMENTAL MODEL | SOURCE | IDENTIFIER |
|--------------------|--------|------------|
| Wild-type Human iPSC line | HipSci | HPSI0714i-kute_4 |
| Wild-type Human iPSC line | HipSci | HPSI0514i-toco_5 |
| Wild-type Human iPSC line | HipSci | HPSI0314i-cuhk_1 |
| Wild-type Human iPSC line | HipSci | HPSI0613i-qanu_1 |
| Wild-type Human iPSC line | HipSci | HPSI0314i-hoik_1 |
| MODY3 Human iPSC line | HipSci | HPSI0614i-zoio_1 |
| MODY3 Human iPSC line | HipSci | HPSI0614i-zoio_2 |
| MODY3 Human iPSC line | HipSci | HPSI0614i-guyj_2 |
| MODY3 Human iPSC line | HipSci | HPSI0614i-kooz_1 |
| CRISPR Human iPSC line | This study | CRISPR-1 |
| CRISPR Human iPSC line | This study | CRISPR-2 |
| CRISPR Human iPSC line | This study | CRISPR-3 |
| CRISPR Human iPSC line | This study | CRISPR-corrected |

### Oligonucleotides

- Primers for RT-qPCR, see Table S1. ([Cardenas-Diaz et al., 2019](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785828/)); This study [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785828/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785828/)
- gRNAs and ssDNA templates for CRISPR-Cas9 strategy, see Table S2. [This study](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785828/)
- Oligonucleotides for constructs used in the biochemical studies, see Table S3. [This study](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785828/)

### Recombinant DNA

- pSpCas9(BB)-2A-GFP (PX458) | Addgene ([Ran et al., 2013](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC48138)) | plasmid #48138 |
- pUltar backbone | Addgene | plasmid #24129 |
- pMD2.G | Addgene | plasmid #12259 |
- paPAX2 | Addgene | plasmid #12260 |

### Software and algorithms

- Imaris | Bitplane | [https://imaris.oxinst.com/packages](https://imaris.oxinst.com/packages) |
### RESOURCE AVAILABILITY

#### Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Rocio Sancho (rocio.sancho@kcl.ac.uk).

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| ImageJ              | (Schneider et al., 2012) | https://imagej.nih.gov/ij/ |
| RStudio 3.6.1       | RStudio | https://www.rstudio.com/ |
| Prism 7 for MacOS   | GraphPad | https://www.graphpad.com/scientificsoftware/prism |
| FastQC              | (Andrews, 2010) | http://www.bioinformatics.babraham.ac.uk/projects/fastqc |
| CRISPR Finder tool  | Wellcome Sanger Institute Genome Editing (WGE) website | https://wge.stemcell.sanger.ac.uk/find_crisprs |
| Trimomomatic        | (Salge et al., 2014) | http://www.usadellab.org/cms/?page=trimmomatic |
| STAR                | (Dobin and Gingeras, 2015) | https://hbctraining.github.io/Intro-to-rnaseq-hpc-O2/lessons/03_alignment.html |
| featureCount        | (Liao et al., 2013) | https://www.rdocumentation.org/packages/Rsubread/versions/1.22.2/topics/featureCounts |
| ANNOVAR             | (Wang et al., 2010) | https://pubmed.ncbi.nlm.nih.gov/20601685/ |
| Rosalind cluster    | King’s College London | https://rosalind.kcl.ac.uk |

#### Other

| Essential 8 Basal Medium | Gibco | A15169-01 |
|--------------------------|-------|-----------|
| STEMdifit™ Pancreatic Progenitor Kit | Stem Cell Technologies | 05120 |
| Advanced DMEM/F-12        | Gibco | 12634-010 |
| DMEM with 25 mM Glucose   | Gibco | 31966-021 |
| DMEM with 2.8 mM Glucose  | Gibco | 21885-025 |
| Cell recovery solution    | Corning | 354253 |
| Aggrewell™ 400 plates     | Stem Cell Technologies | 34411 |
| ProLong® Gold Antifade Mountant | Fisher | P36930 |
| fish gelatin             | Sigma | G7765-1L |
| BbsI restriction enzyme   | NEB   | R3539S |
| Agel restriction enzyme   | NEB   | R3552S |
| BseRI restriction enzyme  | NEB   | R0581S |
| BamHI restriction enzyme  | NEB   | R3136S |
| EcoRI restriction enzyme  | NEB   | R3101S |
| T4 DNA ligase            | NEB   | M0202 |
| PVDF membranes           | BioRad | 1704156 |
| NaCl                     | Sigma | S9888 |
| KCl                      | Riedel de Haén | 31248 |
| CaCl₂                    | Sigma | C7902 |
| MgSO₄                    | Sigma | M2643 |
| Na₂HPO₄                  | Sigma | S0751 |
| KH₂PO₄                   | Sigma | P0662 |
| NaHCO₃                   | Sigma | S5761 |
| HEPES (powder)           | Sigma | H3375 |
| BSA                      | Sigma | A9647 |
| Glucose                  | Sigma | G5767 |
**Materials availability**

Resources and reagents will be provided upon request. Materials will be provided upon execution of a suitable materials transfer agreement.

**Data and code availability**

- All data are available from the lead contact at request. All high-throughput sequencing data, both raw and processed files, have been deposited in NCBI’s Gene Expression Omnibus and are accessible under accession number: GEO: GSE166822.
- All original code has been deposited at Zenodo and is publicly available as of the date of publication (Zenodo: https://doi.org/10.5281/zenodo.5834882).
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

Human iPSCs were kindly provided through the Human Induced Pluripotent Stem Cell Initiative (HipSci. For this study, 13 different human iPSC lines were used, five derived from healthy donors: kute4 – female, 25-29 years old; toco5 – female, 55-59 years old; cuhk1 – female, 45-49 years old; gauu1 – female, unknown age; hoik1 – female, 40-44 years old, five derived from MODY3 patients: zoio1, zoio2 – female, 75-79 years old; guyj2 – female, 50-54 years old; koqz1 – female, 25-29 years old; kooz5 – female, 40-44 years old and four generated through CRISPR-Cas9 engineering: CRISPR-1, CRISPR-3 and CRISPR-3, (generated from kute4 – female, 25-29 years old) and CRISPR-corrected, (generated from zoio2 – female, 75-79 years old). Cell authentication and more data on cell lines is available freely through the HipSci website (https://www.hipsci.org/). Human iPSCs were maintained at 37°C and expanded in Essential 8 Basal Medium on 6-well plates pre-coated with Vitronectin, with daily media change and passaging every week using 0.5 mM Ethylenediaminetetraacetic acid (EDTA) solution.

**METHOD DETAILS**

**Differentiation of human iPSCs into pancreatic progenitors**

Human iPSCs were differentiated into pancreatic progenitors for a period of 14 days using the STEMdiff™ Pancreatic Progenitor Kit following manufacturer’s instructions, with some modifications: cell seeding prior to differentiation was 500,000 cells/well for 12-well plates and 42,000 cells/well for 96-well plates and stage 1 was extended to 3 days.

**RT-qPCR**

Differentiated cells at different stages were detached using Accutase for 10 min at 37°C and neutralized with 5% FBS in Dulbecco’s phosphate-buffered saline (DPBS). Cells were centrifuged at 300g for 5 min and kept at –80°C until RNA extraction. RNA extraction was done using the RNeasy mini kit and cDNA was prepared using QuantiTect Reverse transcription kit according to manufacturer’s instructions with 10ng-13ng of cDNA/reaction with different primers (Table S1). Plate was spun at 1000g for 5 min before running on a CFX 384 Touch RT-qPCR machine. Gene expression was determined by normalization to the housekeeping gene GAPDH. Human islet cDNA was kindly provided by Dr Oladapo Olaniero, Prof Shanta Persaud, Dr Bo Liu, Guo Cai Huang and Pratik Choudhary.

**Immunocytochemistry of 2D cells**

Differentiated cells in 96-well plates at different stages were fixed in 4% paraformaldehyde solution diluted in D-PBS for 20 min at 4°C, followed by wash and storage in D-PBS. Alternatively, 2D progenitors and HEK293A cells were cultured on 12-well glass bottomed plates and fixed as above. Cells were washed three times in D-PBS and incubated in 100 μl of 0.1-0.5% Triton X-100 in D-PBS with 10% donkey serum for 20 min at RT. Cells were incubated with 100 μl of 0.1-0.5% Triton X-100 in D-PBS with 1% donkey serum containing primary antibodies overnight at 4°C. Cells were washed three times in D-PBS and then incubated with 100 μl of 0.1-0.5% Triton X-100 in D-PBS with 1% donkey serum containing secondary antibodies for 1 hr at RT. Cells were washed three times in D-PBS and DAPI (1:1000) was added to the first wash. Stained cells were visualized using the Operetta CLSM™ High-Content Analysis System or the Leica SP8 confocal microscope.

**Immunohistochemistry of 3D organoids**

Expanding organoids in Matrigel were washed twice in ice-cold D-PBS and retrieved from Matrigel using 500 μl Cell recovery solution through incubation for 30 min on ice, followed by neutralization with cold DMEM, D-PBS and spinning at 4000g for 5 min. From this stage, both retrieved expanded organoids or differentiated organoids in Aggrewell plates were fixed in 1 ml of 4% paraformaldehyde solution in D-PBS for 30 min on ice. The organoids were washed thrice in cold D-PBS and either maintained at 4°C or embedded for sectioning. For embedding, the organoids in D-PBS were equilibrated in an equal volume of 30% sucrose for 15 min at RT. OCT Embedding Matrix was added up to the 750 μl mark without bubbles and sucrose was diluted by using a pipette tip to swirl gently. Tubes were spun in both directions at 3000g for 4 min in a microcentrifuge, allowing organoids to settle at the bottom of the tubes. Organoids were aspirated using a P1000 cut pipette tip and transferred to a prepared OCT-containing chalk in a recognizable col-
umn. Chalks were transferred to dry ice to allow solidification and further kept at -80°C or used for cryosectioning into 10 μm sections. For staining, slides were incubated with 0.5% Triton X-100 in D-PBS for 5 min at RT in dark. Sections were then incubated for 1 hr at RT in the dark with blocking buffer containing PBS, 10% fetal bovine serum (FBS), 3% bovine serum albumin (BSA), 0.05% Triton X-100, 0.05% Tween 20 and 0.25% fish gelatin. Primary antibodies were diluted accordingly in blocking buffer and added to the sections overnight at 4°C in the dark. Next day, sections were washed thrice with D-PBS and incubated with secondary antibodies and DAPI (1/1000) for 1-2h at RT in the dark. Sections were washed thrice with D-PBS and mounted using ProLong® Gold Antifade Mountant and a coverslip.

**Flow cytometry analysis**

At the end of pancreatic progenitor stage, differentiated cells were detached using Accutase for 10 min at 37°C, neutralized with 5% FBS in DPBS and centrifuged at 300g for 5 min and fixed using the Cytofix™ Fixation buffer for 20 min at 4°C. Cells were washed in Pharamingen™ Stain Buffer (FBS) and at least 100,000 cells were used per staining. Cells were permeabilized using the Phosflow™ Permeabilization Buffer III on ice for 30 min. Cells were washed twice in Stain Buffer and incubated with 100 μl Stain Buffer containing conjugated antibodies for 30 min at RT in the dark. Cells were washed three times with Stain Buffer, filtered and analysed using Canto1 machine.

**Expansion of pancreatic progenitor organoids**

At the end of differentiation into pancreatic progenitors, cells were detached using Accutase for 10 min at 37°C, neutralized with 5% FBS in DPBS and centrifuged at 300g for 5 min. The cell pellet was resuspended in approximately 300 μl Growth Factor Reduced (GFR) Matrigel® and 25 μl of the cell culture suspension was seeded in pre-warmed 24-well plates. Plates were incubated for 10 min at 37°C to allow solidification. 500 μl of Expansion Media containing Advanced DMEM/F-12, 1 Μ HEPES, 1XGlutamax supplement, 1% Penicillin/Streptomycin, 0.5μM A83-01, 0.05 μg/ml mouse EGF, 0.1 μg/ml human FGF-10, 0.01 μl Gastrin, 1.25mM N-acetylcysteine, 10mM Nicotinamide, 1XB27 supplement and 10% Noggin and R-spondin-conditioned-media with 10.5μM Y-27631 as published by others (Boj et al., 2015; Huch et al., 2013) was added to each well for the first 2-3 days. Media was changed every 2-3 days excluding Y-27631. Organoids were expanded for 7-10 days before splitting. Organoids were split using TrypLE for 5 min on a 37°C shaker. D-PBS was added to neutralize TrypLE, cells were centrifuged at 5000g and resuspended in Matrigel (1/4 or 1/6 split ratio) and expanded as described above. Organoids were expanded up to passage 15, frozen at different passages in Expansion Media with 10% dimethyl sulfoxide (DMSO) and went through freeze-thaw cycles with good recovery.

**Differentiation of pancreatic progenitor organoids**

Organoids were split into single cells using TrypLE and seeded at 375,000 cells/well in Aggrewell™ 400 plates in Expansion Media with 10.5μM Y-27631. Next day, cells were differentiated for 16 days adapting the protocol from Russ and colleagues (Russ et al., 2015) with modifications implemented by Trott and colleagues (Trott et al., 2017): 2 days - DMEM with 25 mM Glucose with 1xB27, 50 ng/ml EGF, 1μM RA; 2 days - DMEM with 25 mM Glucose with 1xB27, 50 ng/ml EGF, 50 ng/ml FGF7, 5 days - DMEM with 25 mM Glucose with 1xB27, 500 nM LDN-193189, 30 nM TBP, 1000 nM ALKi II, 25 ng/ml KGF; 7 days - DMEM with 2.8 mM Glucose, 1,100 Glutamax, 1:100 NEAA. Media change was done daily with 1 ml of media with double amount of growth factors, while cells were maintained on orbital shaker at 100 rpm. Alternatively, domes of Matrigel were detached and transferred to a 6-well plate with 3 ml of differentiation media, following the same protocol as describe above.

**CXCR4 sorting at definitive endoderm stage**

Differentiated iPSCs at DE stage were sorted using CXCR4 MicroBead Kit (Miltenyi Biotec) following manufacturer’s instructions. Briefly, DE cells were harvested using TrypLE, washed with PBS supplemented with BSA and DNase, and counted. Then, cells were immunostained with CXCR4-APC antibody for 10 min at 4°C. Immunostained cells were washed and mixed with Anti-APC MicroBeads for 15 min at 4°C. After washing, cells/beads mix was passed through MACS LS Columns (Miltenyi Biotec) to perform magnetic separation. CXCR4 positive and negative cells were directly re-seeded in vitronectin coated plates to continue their differentiation to PP.

**Glucose stimulated insulin secretion (GSIS)**

GSIS was performed to study the ability of differentiated cells to release insulin in response to glucose, as previously described (Truchan et al., 2015). Briefly, at the end of the differentiation, the clusters were washed with PBS and equilibrated for 1h in Krebs buffer (NaCl 128mM, KCl 4.7mM, CaCl2 2.5mM, MgSO4 1.2mM, Na2HPO4 1mM, KH2PO4 1.2mM, NaHCO3 5mM, HEPES 10mM, and BSA 0.1% in distilled water) with 1.7mM glucose. Then, cells were incubated with Krebs buffer with 2.8mM and 16.7mM glucose, 1h each. Next, clusters were dispersed with TrypLE for 5 min and cells were counted using a haemocytometer. The insulin in the supernatants was quantified using Ultrasensitive Insulin ELISA kit (Mercodia).

**CRISPR/Cas9 gRNA and ssDNA design**

The guide RNA (gRNA) was designed to cut the wild-type sequence adjacent to the polyC tract next to a protospacer adjacent motif (PAM) sequence using the CRISPR Finder tool from the Wellcome Sanger Institute Genome Editing (WGE) website.
CRISPR/Cas9 gRNA cloning into PX458 plasmid
The gRNA pairs with sticky BbsI ends were annealed in a thermocycler (95°C for 5 min and then ramped down to 25°C by 5°C/min). The pSpCas9(BB)-2A-GFP (PX458) plasmid was digested with BbsI restriction enzyme, and the ligation components were added to the digested plasmid using T4 DNA ligase according to manufacturer’s instructions. The ligation reaction was transformed in One Shot® TOP10 competent cells according to manufacturer’s instructions. Bacteria were plated in Luria-Bertani (LB) agar plates containing 100 μg/mL of ampicillin and incubated at 37°C for 12-14h. Colonies were picked and expanded overnight in 5 mL LB broth at 37°C. Next day, the LB solution was used for plasmid purification with the MiniPrep kit following manufacturer’s instructions. DNA content of the purified plasmids was quantified using the NanoDrop 2000 spectrophotometer. For checking the integration of gRNAs into the PX458 plasmid, restriction digest reactions were set up with the BbsI and AgeI enzymes as per manufacturer’s instructions.

Transfection of iPSCs with gRNA-PX458 plasmid construct and ssDNA templates
Human iPSC lines were expanded up to 70-90% confluency in 6-well plates prior to transfections using Lipofectamine 3000 according to manufacturer’s instructions. 3 μg of gRNA-PX458 plasmid and 200 μM ssDNA templates were simultaneously transfected in a wild-type line in presence of E8 with 10.5 μM Y-27631 to generate mutant iPSC lines. Cells were checked after 24h under a fluorescent microscope, media was replenished, and cells were allowed to recover for three days before sorting.

FACS-sorting and screening of transfected iPSCs
Transfected iPSCs were prepared for fluorescence-activated cell sorting (FACS) sorting by pre-incubation with fresh E8 media with 10 μM Y-27631 for at least two hours. Cells were dissociated using Accutase for 10 min at 37°C and the cell suspension was neutralized using 10% FBS in D-PBS. Cells were centrifuged for 3 min at 200g and resuspended in FACS-sorting buffer (1x Hank’s Balanced Salt Solution (HBSS), 1mM EDTA, 25mM 2-[4-(2-Hydroxyethyl)-1-piperazinyl]-ethanesulfonic acid (HEPES), 3% FBS and 10μM Y-27631). Live cells were sorted under sterile conditions using the BD Aria 3 in 96-well plates or as serial dilutions in a 6-well plate. Plates were centrifuged for 3 min at 70g to ensure attachment and incubated at 37°C for 48h in E8 media with 10μM Y-27631. Media was changed daily until colonies of 30-50 cells appeared, from when the media was changed to plain E8 media. Individual colonies were picked and transferred to 24-well plates and subsequently to 12-well plates for expansion. Upon confluency, 70% of the well was frozen in E8 with 10% DMSO and 30% of the well was centrifuged for 3 min at 200g and used for screening using Sanger sequencing or/and PCR-based enzyme digestion. Genomic DNA was extracted using DirectPCR Lysis Reagent (Cell) containing 1 mg/ml Proteinase K. Eppendorf tubes were incubated at 55°C for 6h (or overnight) at 500 rpm on a Thermomixer, followed by incubation at 85°C for 45 min and on ice for 5 min. Eppendorf tubes were centrifuged at 13,000 rpm for 5 min and the supernatant was transferred to a new Eppendorf tube, which was further used for PCR/Sanger sequencing (0.5 μl/PCR reaction of 25 μl). Flanking primers were designed to generate a 277 bp fragment around the polyC tract. The fragment was amplified using Q5 high-fidelity DNA polymerase kit according to manufacturer’s instructions on a PCR machine. The generated PCR fragments were either run by DNA electrophoresis or cleaned using the Monarch PCR-cleaning kit and further sequenced by Sanger sequencing using a sequencing primer spanning the generated PCR fragment. Positive clones were expanded and differentiated towards pancreatic progenitors and beta-like cells.

Cloning
Expression of HNF1α/HNF1αmut proteins was achieved by cloning the wild-type HNF1α coding sequence (CDS) and the truncated HNF1α CDS into a pUltra plasmid, with a Flag tag added to allow identification and immunoprecipitation. HNF1α CDS was cloned into a mCherry-pUltra plasmid, where a myc tag was added. For both proteins BamHI and EcoRI were used as restriction sites. Point mutagenesis into HNF1α12H was achieved via site directed mutagenesis PCR, with the Flag-HNF1αmut pUltra as a template. Plasmid expansion was performed using One Shot® TOP10 competent cells, following Midiprep isolation according to manufacturer’s instructions.

Western Blot-IP
HEK293T cells were transfected with the cloning constructs using PEI at a 1:3 proportion. At the end of each procedure, proteins were harvested with NP-40 buffer with the addition of protease inhibitors (NaF 0.1M, PMSF 10mM, Orthovanadate 10mM, Protease inhibitor cocktail). Lysis buffer was left to act for 30 min at 4C, after which cells were centrifuged at 14000 rpm for 10 min at 4C in order to pellet cell debris. Protein supernatant was quantified using Bradford assay to ensure a consistent protein loading and either stored at −80°C or directly prepared for electrophoresis. Samples were prepared by adding 4x Laemmli buffer and boiling at 99°C for 5 min. For IP output, an average of 1000μg of protein was incubated O/N with 50ul anti-Flag beads (M8823, Sigma-Aldrich) at 4C, shaking. The next day, the excessive proteins/beads were washed four times using NP-40 buffer and samples were prepared for loading by boiling for 10 min at 70°C. Gel electrophoresis was performed in casted 10-12% gels, separating 40-80μg of protein for 1hr 45 min at...
CHROMATIN IMMUNOPRECIPITATION

HEK293T were plated at day 0 in 10 mm dishes and transfected the next day with the different construct combinations. 24h after transfection, each sample was crosslinked for 15 min at RT using PFA at a 1% final concentration. The reaction was then neutralized for 5 min with 125mM Glycine. Cells were then scraped and collected in falcon tubes, washed twice with 1x PBS and lysed using IP buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.5, 5 mM EDTA, NP-40 0.5% vol/vol, Triton X-100 1.0% vol/vol) supplemented with protease inhibitor cocktails (Sigma Aldrich). Cell material was then washed twice using IP buffer and centrifugation at 12000g for 90 secs. Pellet was then resuspended to a final volume of 750ul IP buffer and subjected to 6 cycles of 10s sonication using Elmasonic S10 ultrasonic water bath (Camsonix). Sheared chromatin was then split for IP and mock IP, and Input DNA isolation. Mock IP was performed using A/G beads only (Thermo Scientific), while IP was performed using A/G beads loaded with anti HNF1β CHIP validated antibody (#720259, Thermo Scientific). After overnight incubation of the samples at 4C, samples were centrifuged at 12000g, beads were washed 5 times using IP buffer and resuspended to a final volume of 40ul. A 1:1 volume of 10% Chelex-100 (142-1253, Biorad) was added to all samples (IP, mock IP and DNA isolated from input samples), which were then vortexed for 10s before boiling at 98C for 10 min. Once samples cooled from the boiling, the optional step of Proteinase K digestion was performed by adding 1ul of 20 mg/ml Proteinase K and incubating for 30 min at 55C, shaking at 1000 rpm. A re-boiling step at 98C for 10 min was performed to inactivate Proteinase K. The DNA of each condition was then isolated by centrifugation at 12000g for 1.30 min at 4C, collecting the supernatant, washing the beads-chexel or chexel mix with an 100ul of ultrapure water, centrifuging again at 12000g for 1.30 min at 4C and adding the supernatant to the previously collected one. Finally, 2ul of isolated DNA was used for each RT-qPCR reaction (See RT-qPCR section).

LENTIVIRAL PRODUCTION AND INFECTION

Lentiviral particles were produced by transfecting HEK293T with the plasmids pMD2.G, psPAX2 and the transgene-pUltra plasmids in the proportion 1:4:1:5:4 using PEI 1:3. Supernatant containing lentivirus was collected at 48 and 72h, cleared of cell debris via centrifugation at 500g for 5 min and filtration through a 0.45 µm filter. Lentiviral particles were left to concentrate using Lenti-X concentrator at 4C O/N. The next day, the virus was further concentrated via centrifugation at 1500 rpm for 45 min at 4C and then resuspended in Optimem. Viral titer was determined using HEK cells before use. To generate stable lines, cells were plated in 2D at day 0 at a density allowing a confluence of 70-80% for the next day. Cells were exposed to the virus resuspended in fresh media with the addition of 1:1000 polybrene to aid viral function. At Day 2, viral media was removed, and cells were monitored until GFP expression was assessed. Upon fluorophore expression, cells were FACS-sorted to isolate transgene expressing cells and purity was assessed.

EXOME-SEQUENCING

Exome sequencing files were provided by HipSci through the European Genome-Phenome Archive (EGA) interface. Raw files were filtered for higher confidence variants using Impute2 (Howie et al., 2009) by HipSci. Non-synonymous single-nucleotide variants (nsSNVs) from the imputed and phased files were mapped to gene and protein sequences using the ANNOtate VARiation (ANNOVAR) tool (Wang et al., 2010) to identify and confirm the p291fsinsC mutation in the MODY3 patient iPSC lines.

RNA-SEQUENCING

Poly-A+ RNA was isolated from total RNA and cDNA libraries were constructed according to standardized Illumina protocols performed by Genewiz. High-throughput sequencing was performed using an Illumina HiSeq 2000 sequencer. At least 30 million 150 bp paired reads were obtained per sample with a mean quality score of 35-37. The raw RNA-sequencing read files were processed using the research computing facility at King’s College London, Rosalind (https://rosalind.kcl.ac.uk). RNA-sequencing reads were trimmed from adapters using Trimmomatic/0.39 (Bolger et al., 2014) and quality control was done using FASTQC/0.11.8 (Andrews, 2010). Reads were mapped to a concatenated genome sequence of human GRCh38/hg38 using STAR/2.4.2 (Dobin and Gnerals, 2015). Transcript abundance was measured using featureCount in Subread package (Liao et al., 2013). The DESeq2 package (Love et al., 2014) was used to identify differentially expressed genes. Volcano plots were created using the EnhancedVolcano package, heatmaps were made using the heatmap.2 function in the gplots package and PCA was performed using the plotPCA function in the DESeq2 package in R3.5.5.
QUANTIFICATION AND STATISTICAL ANALYSIS

All differentiation experiments represent at least three biological replicates with similar results. All the graphs show mean values per group, with error bars representative of S.E.M. Specific P-values for each figure are represented in the graphs. Two-tailed Student’s t-test was performed for Figures 1, 2, and 4E and one-way ANOVA followed by Tukey’s test was performed for Figures 3, 4C, 5, 6, 7, S6, and S7; two-way ANOVA followed by Sidak’s multiple comparison test for Figure 4F. Statistical analysis was performed using the software GraphPad Prism 8. Differentially expressed genes were generated using the negative binomial generalized linear models for expressed genes in DESeq2 and Wald test to compare 2 groups in Figures 5 and S6. Sample sizes are reported in each figure legend. Image quantification was done through manual counting, using Imaris 9.2.0 or ImageJ 2.1.0.